Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The N-acetyltransferase-2 gene (NAT-2) has been associated with Parkinson's disease. The genotype associated with slow acetylation has been reported to be increased in patients with Parkinson's disease. Three mutant alleles M1, M2, and M3 of NAT-2 were investigated in 80 patients with idiopathic Parkinson's disease and 161 age matched randomly selected controls from a prospective population based cohort study. The allelic frequencies and genotypic distributions in patients were very similar to those found in controls. In controls the frequency of the wild type allele increased significantly with age suggesting that the mutant alleles are associated with an increased risk of mortality. These findings suggest that NAT-2 polymorphism is not a major genetic determinant of idiopathic Parkinson's disease, but may be a determinant of mortality in the general population.

Original publication

DOI

10.1136/jnnp.67.4.518

Type

Journal article

Journal

Journal of neurology, neurosurgery, and psychiatry

Publication Date

10/1999

Volume

67

Pages

518 - 520

Addresses

Department of Epidemiology and Biostatistics, Erasmus University Medical School, PO Box 1738, 3000 DR Rotterdam, The Netherlands.

Keywords

Humans, Parkinson Disease, Arylamine N-Acetyltransferase, Prospective Studies, Genotype, Polymorphism, Genetic, Aged, Aged, 80 and over, Middle Aged, Netherlands, Female, Male